CStone Pharmaceuticals Share Price Deutsche Boerse AG
Stocks
PH4
KYG2588M1006
Pharmaceuticals
OTC Markets Traded|
Delayed
Deutsche Boerse AG
01:25:01 11/09/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 0.6158 EUR | -5.87% |
|
-17.34% | +8.04% |
| 07/09 | CStone Pharmaceuticals Joins Stock Connect Southbound Trading | MT |
| 31/08 | Cstone Pharmaceuticals Provides Updates on Cs2009 and Pipeline 2.0 Clinical Trials and Product Portfolio | CI |
| Market Cap | 788.84Cr 117.58Cr 101.31Cr 96Cr 87Cr 163.12Cr 11TCr 163.95Cr 1.14TCr 438.12Cr 5.72TCr 441.6Cr 431.91Cr 18TCr | P/E 2026 * |
-17.1x | P/E 2027 * | 8.29x |
|---|---|---|---|---|---|
| Enterprise Value | 691.07Cr 103.01Cr 89Cr 84Cr 76Cr 142.9Cr 9.84TCr 143.63Cr 998.11Cr 383.82Cr 5.01TCr 386.87Cr 378.38Cr 16TCr | EV / Sales 2026 * |
16.3x | EV / Sales 2027 * | 2.24x |
| Free-Float |
79.92% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Hong Kong S.E.
| 2616 | Delayed | |
OTC Markets
| CSPHF | Delayed | |
|
Tradegate
| PH4 | Real-time | |
|
Deutsche Boerse AG
| PH4 | Delayed | |
|
Börse Stuttgart
| PH4 | Delayed | |
|
Boerse Muenchen
| PH4 | Real-time |
Last Transcript : CStone Pharmaceuticals
| 1 day | -5.87% | ||
| 1 week | -17.34% | ||
| Current month | +0.88% | ||
| 1 month | -3.39% | ||
| 3 months | +30.14% | ||
| 6 months | -20.54% | ||
| Current year | +8.04% |
| 1 week | 0.62 |  | 0.67 |
| 1 month | 0.55 | | 0.74 |
| Current year | 0.45 | | 1.12 |
| 1 year | 0.45 | | 1.12 |
| 3 years | 0.09 | | 1.35 |
| 5 years | 0.09 | | 1.35 |
| 10 years | 0.09 | | 1.98 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jian Xin Yang
CEO | Chief Executive Officer | 62 | 25/08/2022 |
Wei Cong Ni
DFI | Director of Finance/CFO | - | 18/01/2023 |
Ying Hua Zhang
COO | Chief Operating Officer | 46 | 01/08/2016 |
| Director | Title | Age | Since |
|---|---|---|---|
Wei Li
CHM | Chairman | 55 | - |
Jian Xin Yang
BRD | Director/Board Member | 62 | 25/08/2022 |
Edward Hu
BRD | Director/Board Member | 63 | 09/07/2021 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -5.87% | -17.34% | - | - | 123.61Cr | |
| -1.34% | -5.51% | +37.65% | -6.17% | 7.92TCr | |
| -1.42% | -4.79% | -20.78% | -38.31% | 5.82TCr | |
| +8.73% | +1.56% | +482.18% | +39.71% | 5.45TCr | |
| -0.56% | -4.20% | -11.00% | +27.11% | 4.89TCr | |
| +1.93% | -2.37% | -2.00% | +149.45% | 4.47TCr | |
| +1.18% | -1.49% | +46.16% | -15.98% | 3.18TCr | |
| -0.37% | -3.35% | +42.16% | +90.19% | 2.5TCr | |
| -0.85% | -8.82% | -6.07% | +164.64% | 2.09TCr | |
| -0.09% | -3.61% | +63.58% | +97.66% | 1.58TCr | |
| Average | +0.11% | -5.31% | +70.21% | +56.48% | 4.21TCr | |
| Weighted average by Cap. | +0.89% | -5.38% | +81.35% | +37.43% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 42Cr 6.31Cr 5.43Cr 5.15Cr 4.66Cr 8.75Cr 602.59Cr 8.79Cr 61Cr 24Cr 306.57Cr 24Cr 23Cr 968.73Cr | 172.22Cr 26Cr 22Cr 21Cr 19Cr 36Cr 2.45TCr 36Cr 248.74Cr 96Cr 1.25TCr 96Cr 94Cr 3.94TCr |
| Net income | -38Cr -5.72Cr -4.93Cr -4.66Cr -4.23Cr -7.93Cr -546.19Cr -7.97Cr -55Cr -21Cr -277.88Cr -21Cr -21Cr -878.06Cr | 68Cr 10Cr 8.74Cr 8.27Cr 7.5Cr 14Cr 969Cr 14Cr 98Cr 38Cr 492.99Cr 38Cr 37Cr 1.56TCr |
| Net Debt | -98Cr -15Cr -13Cr -12Cr -11Cr -20Cr -1.39TCr -20Cr -141.21Cr -54Cr -708.33Cr -55Cr -54Cr -2.24TCr | -402.28Cr -60Cr -52Cr -49Cr -44Cr -83Cr -5.73TCr -84Cr -581.01Cr -223.42Cr -2.91TCr -225.2Cr -220.26Cr -9.21TCr |
| Date | Price | Change |
|---|---|---|
| 11/26/11 | €0.6158 | -5.87% |
| 10/26/10 | €0.6542 | +0.49% |
| 09/26/09 | €0.6510 | -1.45% |
| 08/26/08 | €0.6606 | +2.17% |
| 07/26/07 | €0.6466 | -13.21% |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 2616 Stock
- PH4 Stock
Select your edition
All financial news and data tailored to specific country editions
